Press Releases

06.26.25

Press Release

Achieve Life Sciences Announces Proposed Underwritten Public Offering

SEATTLE, Wash. and VANCOUVER, British Columbia, June 26, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares…

/Read More

06.26.25

Press Release

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy  Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need Seattle and Vancouver, British Columbia, June 26, 2025  — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company…

/Read More

06.26.25

Press Release

Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation

Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades  More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s…

/Read More

05.28.25

Press Release

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

SEATTLE and VANCOUVER, British Columbia, May 28, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will present at the Jefferies Global Healthcare Conference being held June 3–5,…

/Read More

05.20.25

Press Release

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

Oral Presentation to Highlight Key Benefits of Cytisinicline’s Dual Mechanism of Action to Pulmonary Specialists SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today…

/Read More